In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $58.00. The company’s shares opened today at $8.09.
According to TipRanks, Roy is an analyst with an average return of -3.6% and a 27.48% success rate. Roy covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, Oncolytics Biotech, and Day One Biopharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Anavex Life Sciences with a $45.00 average price target, implying a 456.24% upside from current levels. In a report released on June 15, Berenberg Bank also reiterated a Buy rating on the stock with a $40.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Anavex Life Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $13.11 million. In comparison, last year the company had a GAAP net loss of $10.44 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Read More on AVXL:
- Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome
- Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem
- Anavex, Partex Group announce strategic partnership to leverage AI
- Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
- ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome
